"Your health and safety are always our top priority. To help you protect yourself and your loved ones, we’ve gathered the most important information and guidance on the coronavirus and COVID-19. Go to our website. You have many ways to get care without leaving the comfort of your home - including an e-visit, phone, video appointments, and email. This allows you to still get great care while helping to address the community spread of COVID-19. If you’re concerned about your specific health condition, call 1-833-KP4CARE (1-833-574-2273) (TTY 711) to talk to a licensed care provider 24/7. For answers to your general questions about COVID-19, call our new information line for Kaiser Permanente members at 1-877-813-7297."

During the past decade, Kaiser Foundation Hosp conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kaiser Foundation Hosp" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 6 trials, followed by "Gilead Sciences" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Celcuity, Inc." with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaiser Foundation Hosp" #1 collaborator was "Glaxo Wellcome" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Kaiser Foundation Hosp" are "HIV Infections" (7 trials), "Pneumonia, Pneumocystis Carinii" (3 trials), "COVID-19" (2 trials), "West Nile Virus" (2 trials) and "Atherosclerosis" (1 trials). Many other conditions were trialed in "Kaiser Foundation Hosp" in a lesser frequency.

Most popular intervention types in "Kaiser Foundation Hosp" are "Drug" (9 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Zalcitabine" (3 trials), "Atovaquone" (2 trials), "Placebo" (2 trials), "Remdesivir" (2 trials) and "Standard of Care" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kaiser Foundation Hosp" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Kaiser Foundation Hosp". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Kaiser Foundation Hosp, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kaiser Foundation Hosp, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".